About Lisa Lewin

This author has not yet filled in any details.
So far Lisa Lewin has created 9 blog entries.

Precision Medicine Group Appoints John Hubbard, PhD, as Board of Directors Chair

2023-03-14T08:34:11-04:00News, Press Releases|

BETHESDA, MD, March 14, 2023 – Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of John Hubbard, PhD, as Chairman of its Board of Directors.

“We are thrilled to welcome John to our Board. He is a highly regarded leader in the pharmaceutical industry with extensive experience in clinical development and operations, strategic planning and business development,” said Mark Clein, Chief Executive Officer of Precision Medicine Group. “His impressive qualifications make him uniquely qualified to appreciate the breadth of services offered across our organization and to provide valuable insight as we continue to expand our global footprint and integrated capabilities.”

(more…)

Stern IR Launches an ESG Advisory Practice

2023-03-14T07:43:51-04:00News, Press Releases|

Stern IR, part of Precision Value & Health, enhances market leadership position by integrating IR expertise, deep biotech knowledge, and ESG solutions to bring substantive value to clients. ESG Expert Molly Podolefsky, PhD, to lead complementary new ESG capability

NEW YORKMarch 2, 2023 — Stern IR, Inc., a Precision Value & Health company, today announced the launch of its new environmental, social, and governance (ESG) advisory practice. The addition of the ESG practice will deliver a suite of solutions, including materiality assessments, ESG strategy and roadmap development, reporting, and communications packages that are well integrated with Stern’s core investor relations (IR) competencies. These complementary ESG solutions are designed to meet the evolving IR needs of biotechnology and healthcare companies, which increasingly involve and are influenced by ESG considerations and factors with ESG rapidly becoming a core component of best-in-class IR.

(more…)

Article: Weathering the Storm: Cell and Gene’s Economic Downturn

2023-02-21T15:31:12-05:00Cell & Gene Therapy|

After record-setting milestones in fundraising over the past two years, the advanced therapy investment landscape is experiencing a natural correction. Precision’s Anshul Mangal and Dr. James M. Wilson outline in this The Medicine Maker article how industry leaders can ensure the advancement of innovative treatments for patients with #rarediseases by consolidating investments and prioritizing partnerships with patient advocacy organizations.

(more…)

QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)

2023-02-01T16:43:47-05:00News, Press Releases|

QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity.

[Frederick, MD – January 24, 2023] Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.

SolveBio’s intelligent technologies and enterprise data management platform has integrated into QuartzBio’s suite of SaaS solutions, providing a single, scalable solution supporting clinical sample inventory management and biomarker data management for the biotech and pharmaceutical sectors.

(more…)

PRECISION VALUE & HEALTH NAMES DOUG FULLING PRESIDENT

2023-01-26T09:14:41-05:00News, Press Releases|

Proven Life Sciences Leader Takes Reins to Continue Rapid Growth and
Drive Next-Gen Commercialization Model

BETHESDA, MD (January 26, 2023) Precision Value & Health (PVH), today announces that Doug Fulling has joined as President. As the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, Doug will be accountable for the overall strategy, organizational leadership, financial performance, and next-level growth of this market-leading commercial enterprise.

(more…)

New Tech on the Rise: The Future of Cell and Gene Therapies Is Here

2023-01-19T07:17:38-05:00Cell & Gene Therapy|

Recent headlines suggest that the biotech industry as a whole is experiencing a downturn, yet in spite of this narrative the momentum for advanced therapies continues to persevere. Many companies in the cell and gene therapy space are dedicated to bringing these novel therapies to the patients who need them. In this article for PM360 Magazine, Precision’s Anshul Mangal explores the breakthroughs taking place in autologous cell therapies, non-viral delivery methods, and gene editing technologies that may improve patient access for life-saving treatments.

(more…)

Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics

2022-11-08T19:39:15-05:00News, Press Releases|

BETHESDA, MD — Nov. 3, 2022 — Precision for Medicine, the first biomarker-driven clinical research organization (CRO) supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, announces the culmination of a groundbreaking Next Generation Sequencing (NGS) initiative which improved the accuracy and speed of identifying cancer mutations in solid tumors, allowing researchers and manufacturers to develop patient-specific diagnostics for improved clinical outcomes.

(more…)